Donna (Campbell) Milligan, RN
Donna (Campbell) Milligan, RN is an accomplished Registered Nurse and Study Coordinator at Life Pediatric Endocrinology, bringing more than three decades of pediatric nursing experience and nearly two decades in clinical research. Her career reflects a deep dedication to advancing pediatric endocrinology through compassionate care and research excellence. At Life Pediatric Endocrinology, Donna plays a vital role in coordinating studies that improve treatments and outcomes for children, combining her clinical expertise with strong organizational and leadership skills.
Before joining Life Pediatric Endocrinology, Donna spent many years with Rocky Mountain Pediatric Endocrinology (RMPE), where she served as Study Coordinator, RN, and Office Manager. During her tenure, she helped lead high-enrollment clinical trials for all three long-acting growth hormones recently approved by the FDA. Her commitment to precision and compliance was evident through two successful FDA audits—most recently in September 2022—with zero findings or observations, a testament to her thoroughness and professionalism.
In addition to her clinical and research achievements, Donna is a respected national speaker for organizations such as Ascendis Pharma and Novo Nordisk, where she shares her expertise on topics including study coordination and FDA audit preparedness. Known for her exceptional communication, multitasking, and IV skills, she continues to inspire her peers through her dedication to excellence and patient-centered care. Donna’s career exemplifies the balance of scientific rigor and compassion that defines modern pediatric healthcare.
• The University of Texas at Arlington - BSN, Registered Nursing/Registered Nurse
• PENS
Areas of Specialization/Expertise
- Pediatric Endocrinology
What do you enjoy most about practicing medicine?
What I enjoy most about practicing medicine is knowing that my work directly contributes to improving the lives of children and their families. I take great pride in being part of groundbreaking clinical research that leads to real-world medical advancements. I’m especially proud to have been involved in studies that resulted in FDA approval for two of the three long-acting growth hormones now available. Additionally, I take great satisfaction in having successfully completed multiple FDA audits with no findings—an achievement that reflects my commitment to accuracy, compliance, and the highest standards of patient care.